Array BioPharma (ARRY) Statistics

Array BioPharma Inc (ARRY) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of targeted small molecule drugs to treat patients with cancer and other diseases. The company utilizes its proprietary drug discovery platform to identify potential drug candidates and then works to advance them through clinical trials and regulatory approval. ARRY stock statistics indicate that the company has a market capitalization of $10.5 billion and an average daily trading volume of 4.2 million shares. The stock has a 52-week high of $34.59 and a 52-week low of $14.51. As of the most recent quarter, the stock has a price-to-earnings ratio of 51.32 and a price-to-sales ratio of 12.93.

When it comes to valuation metrics, Array BioPharma Inc is currently trading at a forward price-to-earnings ratio of 41.52, indicating that investors have relatively high expectations for the company's future earnings growth. The company also has a price-to-book ratio of 6.25, which suggests that the stock may be slightly overvalued compared to its book value. Looking at the company's fundamentals, Array BioPharma Inc has a return on equity of -5.12% and a return on assets of -3.41%. These figures indicate that the company has not been able to generate consistent profitability and may be facing some challenges in its operations. In terms of stock performance compared to its sector, ARRY has outperformed the industry average with a year-to-date return of 27.64% compared to the sector average of 15.89%.